Related Experiment Video
Updated: Jan 26, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Cardiotoxicity due to targeted anticancer agents: a growing challenge
1Department of Medicine, Hematology Oncology Division, University of Florida, 1600 SW Archer Road, Gainesville, 32608, FL, USA.
Abstract:
The emergence of various targeted anticancer agents has led us to uncharted territory secondary to their cardiotoxic potential with many burning questions, which in turn has led to the evolution of the cardio-oncology field. These targeted agents differ in their cardiovascular complication (CVC) potential even within the same class and it is very difficult to design screening tests that can predict CVCs. Moreover, there is a need for more research to answer many crucial questions, since these toxicities are unanticipated and can lead to poor overall survival of cancer patients. We still do not clearly understand the mechanism for such toxicity, risk factors, and natural history. A better understanding of the underlying risk factors and identification of biomarkers would help us develop protocols for appropriate monitoring strategies which in turn would help capture these toxicities at early stages. In this succinct review, we try to focus on CVC definition, summarize some published research, and point to areas of unmet need in this new field.
Insights
Targeted anticancer agents can cause cardiotoxicity, leading to the growth of cardio-oncology. More research is needed to understand and predict these cardiovascular complications (CVCs) for better patient survival.
Area of Science:
- Cardio-oncology
- Oncology
- Cardiology
Background:
- Targeted anticancer therapies present unique challenges due to their cardiotoxic potential.
- Cardiovascular complications (CVCs) vary significantly among agents, complicating prediction and screening.
- The mechanisms, risk factors, and natural history of these toxicities remain poorly understood.
Discussion:
- The field of cardio-oncology is rapidly evolving to address the cardiovascular risks associated with cancer treatments.
- Developing predictive screening tests for CVCs is difficult due to inter-agent variability.
- Unanticipated toxicities can negatively impact overall survival in cancer patients.
Key Insights:
- Understanding the mechanisms and risk factors for CVCs is crucial.
- Biomarker identification is essential for developing effective monitoring strategies.
- Early detection of CVCs can improve patient outcomes and survival.
Outlook:
- Further research is imperative to address the unmet needs in cardio-oncology.
- Standardized monitoring protocols are required to manage CVCs effectively.
- Continued investigation will refine risk stratification and personalized treatment approaches.
Related Concept Videos
Subviral Agents
Air-entraining Agents
Masking and Demasking Agents
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
Oral Hypoglycemic Agents: Glinides
Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
Chemical Agents for Microbial Control

